Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology

Volumn 58, Issue 1, 2008, Pages 116-124

  Perlmutter, Amy ^a   Cather, Jennifer ^b   Franks, Billy ^c   Jaracz, Eileen ^c   Menter, Alan ^a  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b Modern Dermatology Aesthetics Center   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CYCLOSPORIN A; HYDROXYUREA; METHOTREXATE; PSORALEN; RETINOID; SALAZOSULFAPYRIDINE; TIOGUANINE;

ACTINIC KERATOSIS; ADULT; ARTHRALGIA; ARTICLE; CELLULITIS; CHILL; CLINICAL EXAMINATION; CLINICAL PRACTICE; COUGHING; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HERPES ZOSTER; HUMAN; INFORMED CONSENT; LARYNX PAIN; LOWER URINARY TRACT SYMPTOM; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDICAL RECORD; MYALGIA; NAUSEA; OPPORTUNISTIC INFECTION; PAIN; PATIENT COMPLIANCE; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; REMISSION; RETROSPECTIVE STUDY; SINUS CONGESTION; SORE THROAT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

CHRONIC DISEASE; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, INTRAMUSCULAR; PSORIASIS; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 37349053805     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.09.030     Document Type: Article

References (20)

1. Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345 (2001) 248-255
2. Krueger G.G., and Ellis C.N. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 148 (2003) 784-788
3. Krueger G.G., Papp K.A., Stough D.B., Loven K.H., Gulliver W.P., and Ellis C.N. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47 (2002) 821-833
4. Lebwohl M., Christophers E., Langley R., Ortonne J.P., Roberts J., and Griffiths C.E.M. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 (2003) 719-727
5. Gordon K.B., and Langley R.G. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2 (2003) 624-628
6. Goffe B., Papp K., Gratton D., Krueger G.G., Darif M., Lee S., et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 27 (2005) 1912-1921
7. Menter A., Cather J.C., Baker D., Farber H.F., Lebwohl M., and Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 54 (2006) 61-63
8. Gribetz C.H., Blum R., Brady C., Cohen S., and Lebwohl M. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 53 (2005) 73-75
9. Ortonne J.P., Khemis A., Koo J.Y.M., and Choi J. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 19 (2005) 556-563
10. Scheinfeld N. Therapy-resistant psoriasis treated with alefacept and subsequent narrow band ultraviolet B phototherapy with total clearing of psoriasis. Dermatol Online J 11 (2005) 7
11. Menter A., and Abramovits W. Rational, sequential, and combination regimens in the treatment of psoriasis. Dermatol Ther 11 (1999) 88-95
12. Holzman G., and Phillips T. An extended 16-week course of alefacept in conjunction with reduced T-cell monitoring for the treatment of chronic plaque psoriasis. [abstract]. J Am Acad Dermatol 52 Suppl (2005) P176
13. Gold M., Hamilton T., Rynearson A., and Mathes B. An open-label community-based study of an extended course of alefacept in the treatment of chronic plaque psoriasis. [abstract]. J Am Acad Dermatol 52 Suppl (2005) P177
14. Gribetz C., and Lebwohl M. Maintenance of response in patients with chronic plaque psoriasis after an extended 16-week course of alefacept psoriasis. [abstract]. J Am Acad Dermatol 54 Suppl (2006) AB204
15. Moul D., and Korman N. An open-label single-center study to assess the safety and efficacy of dose escalation of alefacept 15 mg IM for 6 weeks followed by 6 weeks of 30 mg IM in patients with moderate to severe chronic plaque psoriasis. [abstract]. J Am Acad Dermatol 52 Suppl (2005) P177
16. Fleischer A., McCarty A., Carroll C., and Feldman S. The use of high-dose (30 mg/week) alefacept in patients with chronic plaque psoriasis. [abstract]. J Am Acad Dermatol 56 Suppl (2007) AB180
17. Cantrell W., Capela J., and Elewski B. The safety and efficacy of high-dose alefacept (30 mg for 12 weeks) compared with a loading dose of alefacept (30 mg for 6 weeks, followed by 15 mg for 6 weeks) in patients with plaque psoriasis. [abstract]. J Am Acad Dermatol 54 Suppl (2006) AB209
18. Gordon K.B., Krueger G.G., van de Kerkhof P.C.M., and Gottlieb A.B. Efficacy and safety of multiple courses of alefacept in combination with other psoriasis therapies. [abstract]. J Am Acad Dermatol 52 Suppl (2005) P183
19. Feldman S.R., Menter A., and Koo J.Y. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 150 (2004) 317-326
20. Finlay A.Y., Salek M.S., and Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 206 (2003) 307-315